Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-122780
Filing Date
2024-11-07
Accepted
2024-11-07 07:07:48
Documents
76
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q glue-20240930.htm   iXBRL 10-Q 1950571
2 EX-31.1 glue-ex31_1.htm EX-31.1 17608
3 EX-32.1 glue-ex32_1.htm EX-32.1 10329
  Complete submission text file 0000950170-24-122780.txt   7969934

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT glue-20240930.xsd EX-101.SCH 1142246
79 EXTRACTED XBRL INSTANCE DOCUMENT glue-20240930_htm.xml XML 1362176
Mailing Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118
Business Address 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 617-949-2643
Monte Rosa Therapeutics, Inc. (Filer) CIK: 0001826457 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40522 | Film No.: 241433117
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)